company background image
DVAX

Dynavax TechnologiesNasdaqCM:DVAX Stock Report

Market Cap

US$2.2b

7D

13.2%

1Y

393.6%

Updated

25 Oct, 2021

Data

Company Financials +
DVAX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

DVAX Overview

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.

Dynavax Technologies Competitors

VBI Vaccines

NasdaqCM:VBIV

US$773.1m

Merck

NYSE:MRK

US$206.7b

GlaxoSmithKline

LSE:GSK

UK£71.3b

Price History & Performance

Summary of all time highs, changes and price drops for Dynavax Technologies
Historical stock prices
Current Share PriceUS$19.40
52 Week HighUS$3.58
52 Week LowUS$20.96
Beta1.32
1 Month Change-2.17%
3 Month Change110.87%
1 Year Change393.64%
3 Year Change75.88%
5 Year Change109.73%
Change since IPO-79.36%

Recent News & Updates

Oct 25

The Momentum Investor: Spotlight On Dynavax Technologies

The company has had successful drug trials. Earnings are rising. The stock is in a year-long rally.

Oct 16

Dynavax And TLR Biology: Long-Delayed But Outstanding Success

Dynavax developed CpG 1018 many years ago. The coronavirus pandemic gave CpG 1018 a vast market to tap. The future looks good for DVAX.

Oct 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

DVAXUS BiotechsUS Market
7D13.2%2.7%1.9%
1Y393.6%18.8%33.4%

Return vs Industry: DVAX exceeded the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: DVAX exceeded the US Market which returned 30.3% over the past year.

Price Volatility

Is DVAX's price volatile compared to industry and market?
DVAX volatility
DVAX Beta1.32
Industry Beta0.98
Market Beta1

Stable Share Price: DVAX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: DVAX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1996245Ryan Spencerhttps://www.dynavax.com

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.

Dynavax Technologies Fundamentals Summary

How do Dynavax Technologies's earnings and revenue compare to its market cap?
DVAX fundamental statistics
Market CapUS$2.23b
Earnings (TTM)-US$5.70m
Revenue (TTM)US$169.07m

13.2x

P/S Ratio

-390.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DVAX income statement (TTM)
RevenueUS$169.07m
Cost of RevenueUS$80.55m
Gross ProfitUS$88.51m
ExpensesUS$94.21m
Earnings-US$5.70m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 04, 2021

Earnings per share (EPS)-0.05
Gross Margin52.35%
Net Profit Margin-3.37%
Debt/Equity Ratio263.8%

How did DVAX perform over the long term?

See historical performance and comparison

Valuation

Is Dynavax Technologies undervalued compared to its fair value and its price relative to the market?

26.7x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: DVAX ($19.4) is trading above our estimate of fair value ($13.01)

Significantly Below Fair Value: DVAX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DVAX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: DVAX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DVAX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DVAX is overvalued based on its PB Ratio (26.7x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Dynavax Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-14.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DVAX's earnings are forecast to decline over the next 3 years (-14.2% per year).

Earnings vs Market: DVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DVAX's is expected to become profitable in the next 3 years.

Revenue vs Market: DVAX's revenue is expected to decline over the next 3 years (-2.7% per year).

High Growth Revenue: DVAX's revenue is forecast to decline over the next 3 years (-2.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Dynavax Technologies performed over the past 5 years?

4.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DVAX is currently unprofitable.

Growing Profit Margin: DVAX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DVAX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.

Accelerating Growth: Unable to compare DVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: DVAX has a negative Return on Equity (-6.84%), as it is currently unprofitable.


Financial Health

How is Dynavax Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: DVAX's short term assets ($583.9M) exceed its short term liabilities ($204.6M).

Long Term Liabilities: DVAX's short term assets ($583.9M) exceed its long term liabilities ($359.9M).


Debt to Equity History and Analysis

Debt Level: DVAX's debt to equity ratio (263.8%) is considered high.

Reducing Debt: Insufficient data to determine if DVAX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable DVAX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: DVAX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 4.2% per year.


Dividend

What is Dynavax Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DVAX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DVAX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DVAX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Ryan Spencer (43 yo)

1.83yrs

Tenure

US$1,521,779

Compensation

Mr. Ryan Spencer serves as the Chief Executive Officer and Director of Dynavax Technologies Corp. since December 16, 2019. He had been Co-President and Co-Principal Executive Officer of Dynavax Technologie...


CEO Compensation Analysis

Compensation vs Market: Ryan's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD3.49M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DVAX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: DVAX's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.


Top Shareholders

Company Information

Dynavax Technologies Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Dynavax Technologies Corporation
  • Ticker: DVAX
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.226b
  • Shares outstanding: 114.76m
  • Website: https://www.dynavax.com

Number of Employees


Location

  • Dynavax Technologies Corporation
  • 2100 Powell Street
  • Suite 900
  • EmeryVille
  • California
  • 94608
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 23:13
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.